DuPont Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Submits Dec. 9 a new drug application for the Definity ultrasound contrast agent for echocardiography and abdominal indications. The NDA is based on seven randomized Phase III clinical trials involving 610 patients at 52 U.S. sites. Definity is designed to improve imaging of the liver and kidney, as well as cardiac structure and function